好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Outcome Assessments in TUBB4A-associated Leukoencephalopathies
Child Neurology and Developmental Neurology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-056
Establish the feasibility of clinical outcome assessments (COA) in natural history of TUBB4A-associated leukoencephalopathies.

Hypomyelination with atrophy of basal ganglia and cerebellum (H-ABC) and other TUBB4A-associated leukoencephalopathies have clinical features including hypomyelination, delayed motor development, truncal hypotonia, spasticity and dystonia. Although a spectrum of clinical presentations is known to exist, no studies exist on the use of COA in this disorder.

Individuals were enrolled in an IRB approved natural history study of TUBB4A-associated leukoencephalopathies. The Gross Motor Function Measure 88 (GMFM-88) tool was used to analyze the gross motor function of thirteen patients. The GMFM-88 evaluates five dimensions including (A) laying and rolling, (B) sitting, (C) crawling and kneeling, (D) standing and (E) walking, running and jumping. Results of GMFM-88 were compared to the Gross Motor Functional Classification Score (GMFCS), a five-point score that can be assigned from review of medical records. Genotype was noted in all participating individuals. Scores were compared to normative data. Spearman correlation was performed between GMFM-88 and GMFCS

Gross motor abilities in TUBB4A-associated leukoencephalopathies ranged from GMFM-88 of 2.5-97%. 85% of individuals (11/13) had baseline scores above the tenth percentile on the first dimension (laying and rolling), however, only 54% (7/13) achieved this in the second dimension (sitting), and only 69% achieved a total score of higher than the 10th percentile. Two recurrent mutations were seen: c.763G>A (p.V255I) (n=3) was associated with preserved gross motor function, including independent ambulation (2/3); c.785G>A (p.R262H) (n=3) was associated with severe neurologic outcomes. GMFM-88 was highly correlated with an independently assigned GMFCS (r=-0.83, p=0.0001).

TUBB4A-associated hypomyelinating leukodystrophies are clinically variable, and encompass different subtypes. Novel tools are needed in order to accurately capture the heterogenous gross motor function of patients with H-ABC and other TUBB4A-associated leukoencephalopathies. GMFCS, a simple five point scale, accurately captures motor function in this disorder.

Authors/Disclosures
Adeline Vanderver, MD, FAAN (Children'S Hospital of Philadelphia)
PRESENTER
An immediate family member of Dr. Vanderver has received personal compensation for serving as an employee of Maryland Physician Care. The institution of Dr. Vanderver has received research support from Takeda. The institution of Dr. Vanderver has received research support from Passage Bio. The institution of Dr. Vanderver has received research support from Homology. The institution of Dr. Vanderver has received research support from Eli Lilly. The institution of Dr. Vanderver has received research support from Myrtelle. The institution of Dr. Vanderver has received research support from SynaptixBio. The institution of Dr. Vanderver has received research support from PMD Foundation. The institution of Dr. Vanderver has received research support from Ionis. The institution of Dr. Vanderver has received research support from ISD . The institution of Dr. Vanderver has received research support from Boehringer-Ingelheim. The institution of Dr. Vanderver has received research support from Biogen. The institution of Dr. Vanderver has received research support from Sana. The institution of Dr. Vanderver has received research support from Affinia. The institution of Dr. Vanderver has received research support from BridgeBio. The institution of Dr. Vanderver has received research support from Orchard. The institution of Dr. Vanderver has received research support from Minoryx. The institution of Dr. Vanderver has received research support from Forge Biologics. The institution of Dr. Vanderver has received research support from Vigil. Dr. Vanderver has received intellectual property interests from a discovery or technology relating to health care. Dr. Vanderver has received intellectual property interests from a discovery or technology relating to health care.
Julia Kramer-Golinkoff No disclosure on file
Brittany A. Charsar, MD, PhD (Children's Hospital of Philadelphia) No disclosure on file
Omar Sherbini No disclosure on file
Zachary Cross No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file